ANI operates an experiential wellness platform providing employees access to cultural and local experiences. Companies utilize this benefit to enhance workforce engagement, community, and overall wellness. This access drives increased employee connectivity, positivity, and organizational engagement.

ArgusEye develops sensor systems utilizing nanoplasmonic sensing and fiber optics for real-time monitoring of biological processes. Their technology enables in-line analysis, enhancing efficiency in bioprocessing by providing immediate data on critical quality attributes.

Cinclus Pharma is developing linaprazan glurate, a potassium‑competitive acid blocker prodrug, to provide faster, longer‑lasting gastric acid suppression for patients with moderate to severe erosive GERD and Helicobacter pylori infection. The drug’s reversible PCAB mechanism and extended plasma residence aim to improve healing rates and symptom relief compared with traditional proton pump inhibitors.

The startup develops therapies that utilize mutualistic bacterial strains to synthesize polypeptide hormones in the gut microbiome, targeting metabolic and age-related disorders. This approach aims to reduce the prevalence of conditions such as obesity, diabetes, osteoporosis, and Parkinson's disease by enhancing metabolic and brain function.

Henlez develops biologic therapies specifically targeting recurrent and follicular skin disorders, utilizing advanced formulations to enhance skin health. The company aims to provide effective treatment options that improve patient outcomes and reduce the frequency of flare-ups.

Hoba Therapeutics is developing therapeutic proteins, specifically HB-086 and HB-097, targeting neuropathic pain and sensorineural hearing loss, respectively. These proteins, derived from the neurotrophic factors meteorin and cometin, aim to provide safe and effective treatments for conditions with significant unmet medical needs.

IO Biotech is developing T-win® cancer vaccines that utilize a dual-action mechanism to target and eliminate both tumor cells and immune-suppressive cells within the tumor microenvironment. This approach aims to enhance anti-tumor activity and improve treatment outcomes for patients with melanoma and other tumor types.

Moleculent offers a proximity ligation platform that detects and quantifies receptor‑ligand interactions directly in intact tissue sections, providing functional maps of cell‑cell communication. By combining dual antibody‑based PLA with oligonucleotide amplification and simultaneous protein marker staining, the technology delivers spatially resolved interaction profiles that inform disease mechanism studies and therapeutic target selection for cancer and immunology research.

Pretzel Therapeutics develops therapies targeting mitochondrial dysfunction by utilizing advanced mitochondrial biology techniques. This approach addresses over 50 diseases linked to genetic mitochondrial disorders, affecting 1 in 5,000 individuals.

Purpose Pharma develops and commercializes specialty pharmaceuticals for rare diseases with high unmet medical need. The company brings innovative treatments such as ATTROGY® (diflunisal) to European markets, focusing on hereditary transthyretin-mediated amyloidosis. It also supplies unlicensed medicines to healthcare systems to expand patient access to rare‑disease therapies.

The startup has developed a healthcare application that systematically tracks postoperative symptoms and complaints to enhance patient recovery. By providing healthcare professionals with actionable data, the application improves the safety and quality of postoperative care.

Scenic Biotech develops genomics and immunotherapy technologies to identify and utilize genetic suppressors for therapeutic applications. Their platform targets disease pathways in neuro- and metabolic disorders, enabling the creation of disease-modifying therapies that offer new treatment options for patients.

Sortina Pharma develops small molecule therapeutics that target sortilin to eliminate treatment-resistant cancer stem cells, specifically focusing on triple-negative breast cancer and glioblastoma multiforme. This approach aims to prevent metastasis and enhance the efficacy of conventional therapies, addressing the critical challenge of cancer progression.

Strike Pharma develops individualized immunotherapeutic treatments using its proprietary Adaptable Drug Affinity Conjugate (ADAC™) technology, which targets tumor cells based on the genetic profile of each patient's tumor. This approach enhances therapeutic efficacy while minimizing side effects, addressing the limitations of traditional immunotherapy methods that often overlook efficient drug delivery and stability.